search
The ALCHEMIST Study, targeting tumors stage 1B and above, emphasizes negative surgical margins and allows both preoperative and postoperative enrollment. Non-squamous patients undergo EGFR and ALC genotyping, while squamous patients proceed directly to PD-L1 testing. With the closure of some studies and others in progress, the ALCHEMIST Study stands out with over 6000 patients across 1229 sites, surpassing similar studies sixfold. Noteworthy studies include Adjuvant Chrysin with 133 patients and the Anvil study, which accrued almost 1000 patients in a year. Jacob Sands' study is temporarily paused for adjustments but is expected to resume soon. The ALCHEMIST Study, boasting comprehensive genomic sequencing and robust clinical data, promises impactful results in the coming years, reflecting the collective effort of the surgical community.
